Veru reports muscle data from 5 clinical studies of enobosarm that support the advancement of enobosarm in combination with weight-loss glp-1 drugs, ozempic®, wegovy®, or mounjaro®, to optimize weight loss by preventing muscle wasting and further increasing fat loss in a phase 2b obesity clinical study

-- in 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- weight-loss drugs like ozempic, wegovy, mounjaro and other glp-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles increases risk of muscle weakness, functional limitations, mobility disability, falls, higher hospitalizations, and greater mortality --
VERU Ratings Summary
VERU Quant Ranking